ClinicalTrials.gg
TerminatedNCT03838367Updated Sep 9, 2025Results posted

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

A Phase 1/2 interventional study of 350 mg leronlimab and 525 mg leronlimab in Triple Negative Breast Neoplasms, sponsored by CytoDyn, Inc.. Terminated at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by CytoDyn, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study terminated prematurely due to business reasons. Participants are no longer examined or receiving intervention.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Enrollment
536th of 605
10 · median 52
Started
2019
with 53 others
Phase 1/2
107 of 645
33 open now
Registered
309th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 536th largest by enrollment of the 605 interventional ones that give a count, is one of 54 that started in 2019, is one of 107 in phase 1/2, and was the 309th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC).

Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).

Read the detailed description

Phase Ib

Phase Ib is a dose escalation phase with 3 dose levels (cohorts) of leronlimab (PRO 140) administered in combination with a fixed dose of carboplatin at AUC 5 (area under the curve). This dose finding portion of study will follow a "3+3" designed to determine the maximum tolerated dose (MTD) of leronlimab (PRO 140) administered as subcutaneous (SC) injection in subjects with histologically confirmed mTNBC that express CCR5.

Phase II

Phase II is a single arm study with 30 patients in order to test the hypothesis that the combination of carboplatin AUC 5 intravenously and MTD of leronlimab (PRO 140) SC will increase Progression Free Survival (PFS) in patients with CCR5 + mTNBC.

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • TNBC
  • PRO 140
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a confirmed diagnosis of TNBC. Must demonstrate negative (IHC 0, 1+, or fluorescence in situ hybridization (FISH) negative and ER\<1%, and PR \< 1%, per ASCO/CAP criteria);
  2. Demonstrate CCR5 + by IHC (>10% membranous staining completed at the reference laboratory of Dr. Hallgeir Rui at Medical College of Wisconsin).

    Note: This test will be done as part of the pre-screening period. It will be performed in archival tissue. If is not available then, fresh biopsy will be done;

  3. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion (in case archival tissue is not available);
  4. Patients with stage IV de-novo disease or patients that develop recurrence after completion of or adjuvant therapy are eligible; Note: Patients who have been exposed to carboplatin in neoadjuvant or adjuvant setting will be allowed to enroll, if they have progressed ≥ 6 months from completion of treatment.
  5. Phase 1 study section:

    Subjects must have disease recurrence and progression after ≤ 2 in metastatic setting but untreated with carboplatin;

    Phase 2 study section:

    Subjects must be naive to chemotherapy or untreated with carboplatin in metastatic setting (first-line) OR excluding carboplatin chemotherapy, subjects must have failed first-line combination of chemotherapy and a in metastatic setting;

  6. Patients must have based on v1.1;
  7. Female patients, ≥ 18 years of age;
  8. Patients must exhibit a/an performance status of 0-1;
  9. of at least 6 months;
  10. Patients must have adequate organ and bone marrow function within 28 days prior to registration, as defined below:

    • leukocytes ≥ 3,000/mcL;
    • ≥ 1,500/mcL;
    • ≥ 100,000/mcL;
    • total : within normal institutional limits;
    • (SGOT) \&ALT(SPGT) ≤ 2.5 X institutional (ULN) (applicable to all patients, irrespective of liver disease or metastasis); and
    • creatinine: within normal institutional limits.
  11. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.
  12. Females of (FOCBP) and males must agree to use two medically accepted methods of with hormonal or barrier method of birth control, or abstinence, prior to study entry, for the duration of study participation and for 60 days after the last dose of study drug (Refer to Appendix 1). Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Note: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; and
    • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally for > 12 months).
  13. FOCBP must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and
  14. Patients must have the ability to understand and the willingness to sign a written prior to registration on study.

Exclusion criteria

Exclusion Criteria:

  1. overexpressed/amplified breast cancer (MBC) (Appendix 2 for guidelines from ASCO);
  2. ER and or PR expressing tumors;
  3. Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 28 days prior to enrollment;
  4. Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible;
  5. Patients who have had prior exposure to CCR5 antagonists are not eligible;
  6. Patients who have a known additional that is progressing or requires active treatment are not eligible. Patients who have had a prior diagnosis of cancer and if it has been \<3 years since their last treatment are not eligible. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;
  7. Has an active infection requiring systemic therapy. Note: Patients must complete any treatment with antibiotics prior to registration;
  8. Patients who have a known positive status or known/ active and/or C infection are not eligible;
  9. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;
  10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator;
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; and
  12. Is pregnant or breastfeeding, or expecting to conceive or have children within the projected duration of the trial, starting with the pre-screening or screening visit through the duration of study participation.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin

    Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks

    Drug: 350 mg leronlimab · Drug: AUC 5 Carboplatin

  • Experimental
    Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin

    Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks

    Drug: 525 mg leronlimab · Drug: AUC 5 Carboplatin

  • Experimental
    Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin

    Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks

    Drug: 700 mg leronlimab · Drug: AUC 5 Carboplatin

  • Experimental
    Phase II- MTD to be established for the combination treatment

    MTD PRO 140 SC + AUC 5 Carboplatin

    Drug: AUC 5 Carboplatin · Drug: Maximum Tolerated Dose (MTD) of leronlimab

Interventions

  • leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

    Also known as: PRO 140

  • leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

    Also known as: PRO 140

  • leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

    Also known as: PRO 140

  • Carboplatin is an anticancer drug chemotherapy drug.

    Also known as: Paraplatin

  • The decision on the MTD will be made following the results obtained from Phase I studies

    Also known as: PRO 140

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5

    The MTD is defined as 1 dose level (cohort) below the dose in which dose limiting toxicities (DLTs) were observed in \>= 33% of the participants.

    Time frame: From treatment cycle 1 day 1 (C1D1) until MTD reached (each cycle being 3 weeks), up to 26 weeks

  2. Phase II: Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.

    All patients who received at least one dose of leronlimab (PRO 140) and carboplatin combination was intended to be included in the primary analyses of PFS. The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was planned to be used for objective tumor response assessment.

    Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

Secondary outcomes

  1. Phase I: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) Collected From the Time of First Treatment Until Study Termination to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.

    For Phase I: Adverse events followed National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This will be the Number of Participants with Any Adverse Events (AE) or Serious Adverse Events (SAE) collected from the time of first treatment until study termination to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ metastatic triple negative breast cancer.

    Time frame: From Cycle 1, Day 1 (each treatment cycle is 3 weeks) until last dose of study drug, up to 26 weeks

  2. Phase II: Progression Free Survival (PFS) According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)

    Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1) Trial was terminated prematurely and no efficacy data was collected from the Phase II portion.

    Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

  3. Phase II: Overall Response Rate (ORR, Defined as Complete Response (CR) + Partial Response (PR)), and Clinical Benefit Rate (CBR, Defined as CR + PR + Stable Disease (SD)) in Subjects With CCR5+ mTNBC Treated With Leronlimab (PRO 140) and Carboplatin.

    Phase II: Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)), and clinical benefit rate (CBR, defined as CR + PR + Stable Disease (SD)) in subjects with CCR5+ mTNBC treated with The trial was terminated early, efficacy data is not available

    Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

  4. Phase II: Time to New Metastases (TTNM)

    Trial was terminated prematurely and no efficacy data was collected.

    Time frame: Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

  5. Phase II: The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.

    Phase II: The change from baseline in circulating tumor cells (CTC) level in the peripheral blood. No efficacy data was available due to early termination of the trial.

    Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

  6. Phase II: Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death;

    Phase II: Overall survival defined as time in months from the date of first study treatment to the date of death; No efficacy data is available due to early termination of the trial.

    Time frame: Planned from Day 1 to death from any cause, assessing up to 2 years after completion of treatment.

  7. Phase II: Number, Frequency, and Severity of AEs Collected From the Time of First Treatment Until 12 Weeks After Study Treatment Completion to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.

    Phase II: Number, frequency, and severity of AEs collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC. No safety data was available from the Phase II portion of the trial due to early termination of the study.

    Time frame: Planned from Cycle 1, Day 1 (each treatment cycle is 21 days) to 12 weeks after the last dose of study drug)

Other outcomes

  1. Measure Immune Biomarkers (PD-L1) in CTCs, Metastatic Tissue and Immune Cells Such as Cancer Associated Macrophage-like Cells (CAMLs) and Correlate With Therapeutic Benefit (PFS)

    Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS) No subjects were included in this outcome measure due to early termination of the trial.

    Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

  2. Correlation Between CCR5 Expression (CTCs, CAMLs) and PD- L1 Expression.

    No subjects were included in this outcome measure due to early termination of the trial.

    Time frame: Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

07

Results

Posted Sep 9, 2025
Limitations and caveats
Trial was terminated prematurely prior to Phase II section of the study.

Participant flow

Participant flow — Overall Study
MilestonePhase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination Treatment
Started3430
Completed0000
Not completed3430
Withdrew: Early termination of study3430

Outcome measures

PrimaryPhase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5

The MTD is defined as 1 dose level (cohort) below the dose in which dose limiting toxicities (DLTs) were observed in \>= 33% of the participants.

Time frame:
From treatment cycle 1 day 1 (C1D1) until MTD reached (each cycle being 3 weeks), up to 26 weeks
Reported as:
Number · mg
Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5
mgPhase 1b: Including 3 Dose Levels (Cohort A, Cohort B, and Cohort C)
Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5700
PrimaryPhase II: Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.

All patients who received at least one dose of leronlimab (PRO 140) and carboplatin combination was intended to be included in the primary analyses of PFS. The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was planned to be used for objective tumor response assessment.

Time frame:
Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

No measurements were reported for this outcome.

SecondaryPhase I: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) Collected From the Time of First Treatment Until Study Termination to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.

For Phase I: Adverse events followed National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This will be the Number of Participants with Any Adverse Events (AE) or Serious Adverse Events (SAE) collected from the time of first treatment until study termination to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ metastatic triple negative breast cancer.

Time frame:
From Cycle 1, Day 1 (each treatment cycle is 3 weeks) until last dose of study drug, up to 26 weeks
Reported as:
Count of participants · Participants
Phase I: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) Collected From the Time of First Treatment Until Study Termination to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.
ParticipantsPhase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin
Participants with any AEs342
Participants with any SAEs110
SecondaryPhase II: Progression Free Survival (PFS) According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)

Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1) Trial was terminated prematurely and no efficacy data was collected from the Phase II portion.

Time frame:
Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

No measurements were reported for this outcome.

SecondaryPhase II: Overall Response Rate (ORR, Defined as Complete Response (CR) + Partial Response (PR)), and Clinical Benefit Rate (CBR, Defined as CR + PR + Stable Disease (SD)) in Subjects With CCR5+ mTNBC Treated With Leronlimab (PRO 140) and Carboplatin.

Phase II: Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)), and clinical benefit rate (CBR, defined as CR + PR + Stable Disease (SD)) in subjects with CCR5+ mTNBC treated with The trial was terminated early, efficacy data is not available

Time frame:
Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

No measurements were reported for this outcome.

SecondaryPhase II: Time to New Metastases (TTNM)

Trial was terminated prematurely and no efficacy data was collected.

Time frame:
Planned every 6 to 9 weeks after Phase II study start, until progression or death, assessing up to 2 years after completion of treatment

No measurements were reported for this outcome.

SecondaryPhase II: The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.

Phase II: The change from baseline in circulating tumor cells (CTC) level in the peripheral blood. No efficacy data was available due to early termination of the trial.

Time frame:
Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

No measurements were reported for this outcome.

SecondaryPhase II: Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death;

Phase II: Overall survival defined as time in months from the date of first study treatment to the date of death; No efficacy data is available due to early termination of the trial.

Time frame:
Planned from Day 1 to death from any cause, assessing up to 2 years after completion of treatment.

No measurements were reported for this outcome.

SecondaryPhase II: Number, Frequency, and Severity of AEs Collected From the Time of First Treatment Until 12 Weeks After Study Treatment Completion to Evaluate Safety of Leronlimab (PRO 140) and Carboplatin in Subjects With CCR5+ mTNBC.

Phase II: Number, frequency, and severity of AEs collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC. No safety data was available from the Phase II portion of the trial due to early termination of the study.

Time frame:
Planned from Cycle 1, Day 1 (each treatment cycle is 21 days) to 12 weeks after the last dose of study drug)

No measurements were reported for this outcome.

Other pre-specifiedMeasure Immune Biomarkers (PD-L1) in CTCs, Metastatic Tissue and Immune Cells Such as Cancer Associated Macrophage-like Cells (CAMLs) and Correlate With Therapeutic Benefit (PFS)

Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS) No subjects were included in this outcome measure due to early termination of the trial.

Time frame:
Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

Results for this outcome have not been posted.

Other pre-specifiedCorrelation Between CCR5 Expression (CTCs, CAMLs) and PD- L1 Expression.

No subjects were included in this outcome measure due to early termination of the trial.

Time frame:
Planned every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were reported from the time of first treatment until the early termination of the study to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC (up to approximately 30 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Phase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 Carboplatin0/4 (0%)1/4 (25%)4/4 (100%)
Phase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 Carboplatin0/3 (0%)0/3 (0%)3/3 (100%)
Phase II- MTD to be Established for the Combination Treatment———
Most frequent serious events
Most frequent serious events
EventPhase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination Treatment
SepsisInfections and infestations1/30/40/3—
HeadacheNervous system disorders0/31/40/3—
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPhase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination Treatment
FatigueGeneral disorders1/34/41/3—
HeadacheNervous system disorders1/32/41/3—
HypertensionVascular disorders0/32/40/3—
Back PainMusculoskeletal and connective tissue disorders1/30/40/3—
ErythemaSkin and subcutaneous tissue disorders1/30/40/3—
AnaemiaBlood and lymphatic system disorders1/30/41/3—
Platelet Count DecreasedInvestigations1/30/41/3—
NauseaGastrointestinal disorders1/31/41/3—
Neutrophil Count DecreasedInvestigations1/31/41/3—
ConstipationGastrointestinal disorders1/31/41/3—

Baseline characteristics

All patients who received at least one dose of leronlimab (PRO 140) were included in the baseline analysis population. Study was early terminated and no participants were enrolled to the Phase II arm of the trial.

Age, Categorical
Age, Categorical(Participants)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
<=18 years000—0
Between 18 and 65 years332—8
>=65 years011—2
Age, Continuous
Age, Continuous(years)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
Mean41.67 ± 7.7655.75 ± 11.3261.67 ± 8.73—53.30 ± 12.50
Sex: Female, Male
Sex: Female, Male(Participants)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
Female343—10
Male000—0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
Hispanic or Latino000—0
Not Hispanic or Latino243—9
Unknown or Not Reported100—1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
American Indian or Alaska Native000—0
Asian110—2
Native Hawaiian or Other Pacific Islander000—0
Black or African American000—0
White133—7
More than one race000—0
Unknown or Not Reported100—1
Region of Enrollment
Region of Enrollment(participants)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
United States343—10
Height
Height(cm)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
Mean160.05 ± 2.55162.85 ± 6.23164.30 ± 3.30—162.51 ± 5.11
Weight
Weight(kg)Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort B: 525 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase I-Cohort C: 700 mg PRO 140 SC Weekly + AUC 5 CarboplatinPhase II- MTD to be Established for the Combination TreatmentTotal
Mean85.73 ± 32.0866.50 ± 3.5482.90 ± 11.40—76.60 ± 21.44

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • CD07 Investigational Site
    Chicago, Illinois 60611, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jul 2022, 38 months.

Results were first posted in Sep 2025, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2019
First posted
Feb 12, 2019
StartActual
Apr 22, 2019
Primary completionActual
Jul 15, 2022
CompletionActual
Sep 16, 2022
Results first posted
Sep 9, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03838367
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Apr 22, 2019
Primary completion
Jul 15, 2022
Completion
Sep 16, 2022
Results posted
Sep 9, 2025
Last update
Sep 9, 2025

Study contacts

Jacob Lalezari, MD
study director · CytoDyn, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion